Vendor Intelligence Report: Changsha Duole Technology

Published 3 Jul 2026. 21-page investigative report on who is behind Changsha Duole Technology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 8 Finnrick lab tests, Changsha Duole Technology shows a 50% overall pass rate, with 4 pass and 4 fail. The current Finnrick record covers Retatrutide only. Some lots have passed, but the equal failure record, a retained zero-score certificate, and stricter grading that does not rescue the profile make this a poor safety-first Retatrutide source.

The live storefront now looks larger than the tested record. The xchemi store has expanded into a multi-product RFQ catalog with high-purity marketing claims, including Tirzepatide, Semaglutide and IGF-1 LR3, but Finnrick has no supplied tests for those items. They are unvalidated from Duole, not proven good by the Retatrutide file.

The strongest non-lab finding is a sales-infrastructure bridge. A retained Changsha Duole Retatrutide listing uses contact infrastructure tied to a separate Xingtai chemical network with a public precursor-chemistry catalog. The report keeps the conclusion bounded: overlap in sales contact infrastructure is proven; common ownership or peptide manufacture at that site is not.

Identity and authentication are also thin. The buyer-facing record is a cluster of xchemi/echemi trader-style Duole storefronts, including an Uncertified Store posture, conflicting establishment-history signals, unavailable public WHOIS for duole-tech.com, and a recent Duole peptide SEO domain that now returns 503. Narrow enforcement and affiliate scans found no direct vendor-naming hit or visible coupon-influencer funnel, but little reputation evidence offsets the lab and infrastructure concerns.

Inside the full report:

  • Retatrutide pass/fail record, methodology-divergence chart, trajectory graphic and certificate exhibits
  • xchemi and echemi storefront exhibits across the Duole-branded profile cluster
  • Precursor-network analysis of the retained Retatrutide sales-contact bridge into xttch.com
  • Qichacha/Tianyancha, ImportYeti, OFAC/BIS/FDA and duole-tech.com WHOIS search notes
  • Digital-footprint and authentication review covering nnxfou.com and Telegram/WhatsApp contact reuse
  • Affiliate and reputation scan covering X, coupon pages, Reddit/forum leads and coverage limits

Risk assessment

  • Retatrutide product-quality risk — high: Retatrutide only: Finnrick record is 8 tests, 4 pass / 4 fail, with a 67.28% rating and retained evidence of a zero-score Retatrutide certificate.
  • Untested expanded-catalog quality risk — medium: Tirzepatide, Semaglutide, IGF-1 LR3, Epitalon, Cagrilintide, MOTS-c and other RFQ items carry 99% purity claims but have no supplied Finnrick testing record.
  • Precursor-network affiliation risk — high: A Changsha Duole Retatrutide listing used sales3@xttch.com; xttch.com identifies Xingtai Tuchuang Technology and shows BMK Glycidic Acid, PMK Ethyl Glycidate and 4,4-Piperidinediol HCl.
  • Ownership/manufacturer transparency risk — medium: Visible records show Uncertified Store / Trader status, conflicting establishment claims, no exact Qichacha/Tianyancha match, and inaccessible duole-tech.com WHOIS details.
  • Brand/storefront authentication risk — medium: Multiple Duole storefronts and contacts, unverified nnxfou.com promotional activity now returning 503, and no canonical official-channel or COA-verification framework found.